FDA Approves Takeda's EOHILIA (budesonide oral suspension), the First and Only Oral Treatment in the U.S. for Eosinophilic Esophagitis (EoE) -February 12, 2024 at 08:05 am EST : vimarsana.com

FDA Approves Takeda's EOHILIA (budesonide oral suspension), the First and Only Oral Treatment in the U.S. for Eosinophilic Esophagitis (EoE) -February 12, 2024 at 08:05 am EST

— 12 Weeks of Treatment with EOHILIA May Address Significant Unmet Needs of Patients 11 Years of Age and Older

— EoE Is a Chronic Disease That Can Significantly Impact Patients, with Esophageal...

Related Keywords

United States , Japan , Ikuo Hirano , Takeda Pharmaceutical Company Limited , Drug Administration , Exchange Commission , Northwestern University Feinberg School Of Medicine , Takeda Pharmaceuticals United Statesa Inc , Kennethc Griffin Esophageal Center , Division Of Gastroenterology , Esophageal Center , Northwestern University Feinberg School , Dysphagia Symptom Questionnaire , Brandon Monk , Business Unit , Adrenal Axis , Increased Risk , Steroid Withdrawal , Patients Transferred , Annual Report , Takeda Pharmaceuticals United Statesa , Patient Rep , Markets ,